MetaCap

Agios Pharmaceuticals (AGIO) vs Ultragenyx Pharmaceutical (RARE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Agios Pharmaceuticals (AGIO) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, gaining 9.4% versus a loss of 50.9%. Over five years, AGIO leads with a -24.3% price change compared with -78.5% for RARE. Ultragenyx Pharmaceutical is the larger company by market cap ($1.68 billion vs $1.65 billion), about 1.0 times the size, while Agios Pharmaceuticals is growing revenue faster (+48.0% vs +20.2%).

Ultragenyx Pharmaceutical converts more of its revenue into profit, with a net margin of -85.4% versus -764.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGIO+9.35%RARE-50.94%
+81%+6%-68%
Nov 21, 20251 yearNov 20, 2026
AGIO-27.79%RARE-79.22%
+68%-10%-89%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGIO versus RARE key metrics
MetricAGIORARE
Share price$27.60$16.48
Market cap$1.65B$1.68B
1-day change-4.03%-4.30%
YTD return+1.40%-28.35%
1-year return+9.35%-50.94%
5-year return-24.28%-78.45%
Forward P/E—11.50
EPS (TTM)$-6.31$-5.17
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$54.03M$673.00M
Revenue growth (YoY)+48.03%+20.18%
Net income (latest FY)$-412.78M$-575.00M
Gross margin88.26%—
Operating margin-873.87%-79.49%
Net margin-764.01%-85.44%
52-week high$44.09$39.89
52-week low$24.16$12.73
Distance from 52-week high-37.40%-58.69%
Analyst consensusbuybuy
Avg. price target upside+67.07%+50.49%
Average volume1.06M4.69M
Shares outstanding59.81M101.92M
Employees5391,371
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AGIO has outperformed RARE by 60.3 percentage points over the past year.
  • Ultragenyx Pharmaceutical is more profitable, keeping -85.4 cents of every revenue dollar as net income versus -764.0 cents for Agios Pharmaceuticals.
  • Agios Pharmaceuticals grew revenue faster in its latest fiscal year (+48.03% vs +20.18%).

About Agios Pharmaceuticals

AGIO stock →

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.

Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees

About Ultragenyx Pharmaceutical

RARE stock →

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees

AGIO vs RARE FAQ

Which is bigger, Agios Pharmaceuticals or Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (RARE) is larger, with a market capitalization of $1.68B compared with $1.65B for Agios Pharmaceuticals (AGIO).

Which stock has performed better over the past year, AGIO or RARE?

AGIO returned +9.35% over the past 12 months, compared with -50.94% for RARE (price return, excluding dividends). Past performance does not predict future results.

Are Agios Pharmaceuticals and Ultragenyx Pharmaceutical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons